乙-固醇通过调节AMPK/MLCK抗炎途径来改善性结肠炎
Yuansen Zhang1, Xiaosheng Jin1, Huanhuan Xia2
1Department of Gastroenterology, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, Zhejiang, China.
Journal of biochemical and molecular toxicology
|May 22, 2025
概括
通过向AMPK/MLCK通路,β-醇有效降低性结肠炎 (UC) 中的炎症. 这种天然化合物在治疗炎症性肠病 (IBD) 方面表现有前途.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 性结肠炎 (UC) 是一种普遍存在的炎症性肠病 (IBD),其全球发病率正在增加.
- 了解新型治疗剂的分子机制对于有效的IBD管理至关重要.
研究的目的:
- 为了研究β-固醇 (β-固醇) 对小鼠中硫酸 (DSS) 诱导的大肠炎的抗炎作用.
- 阐明潜在的分子机制,特别是AMP激活蛋白激酶 (AMPK) 和肌轻链激酶 (MLCK) 信号传导的作用.
主要方法:
- 一种DSS诱导的大肠炎小鼠模型被用于评估低剂量 (2毫克/公斤) 和高剂量 (6毫克/公斤) 的β-固醇,并使用硫沙拉作为阳性对照.
- 评估了疾病活动指数 (DAI) 评分,组织学分析和炎症标志物 (NO,MPO,IL-6,iNOS,IL-10) 的表达.
- 在体外研究中,使用脂聚糖 (LPS) 刺激的Caco-2细胞和AMPK抑制剂 (化合物C) 验证了分子机制.
主要成果:
- β-醇显著改善了结肠炎症,降低了DAI得分,改善了组织学.
- 它降低了促炎介质 (NO,MPO,IL-6,iNOS) 和增加了抗炎IL-10.
- β-固醇调节了AMPK/MLCK通路,促进AMPK和抑制MLCK,这种效果在体外得到证实,并且取决于AMPK活性.
结论:
- 通过调节AMPK/MLCK信号通路,β-固醇显示出对性结肠炎的显著治疗潜力.
- 这些发现支持β-sitosterol作为新型AMPK向疗法的潜在候选人,用于控制炎症性肠病.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
Inflammatory Bowel Disease IV: Pharmacological Management
84
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
84
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
290
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
290
Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Inflammatory Bowel Disease I: Ulcerative Colitis
106
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
106


